

Why carry out this study?

- There are only limited data on the clinical effectiveness of liraglutide when used in daily clinical practice outside the controlled setting of a randomized clinical trial.
- Real-life data provide crucial information to evaluate the effectiveness of therapeutics in clinical practice and are being requested more and more frequently by health authorities.
- The French Health Authority requested the current study with 2 years of follow-up to evaluate conditions for prescription, maintenance dose, effectiveness and safety of liraglutide in routine clinical practice.

What was learned from the study?

- The results from this study suggest that the effectiveness of liraglutide in real-world clinical practice is similar to that observed in randomized controlled trials.
- Moreover, the results from this study suggest that treatment with liraglutide translates into therapeutic benefits for patients with type 2 diabetes in routine clinical practice.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Novo Nordisk A/S. Medical writing assistance for this study was provided by Watermeadow Medical, UK. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).